Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier

被引:174
作者
Costantino, L
Gandolfi, F
Tosi, G
Rivasi, F
Vandelli, MA
Forni, F
机构
[1] Univ Modena, Dipartimento Sci Farmaceut, I-41100 Modena, Italy
[2] Univ Modena, Dipartimento Integrato Serv Diagnost, I-41100 Modena, Italy
[3] Univ Modena, Lab Med Legale, I-41100 Modena, Italy
关键词
nanoparticles; blood-brain barrier; peptides; targeting; PLGA;
D O I
10.1016/j.jconrel.2005.07.013
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Injectable nanoparticulate drug carriers (Np) able to cross the blood-brain barrier (131313) have important potential applications for the treatment of diseases that affect the central nervous system (CNS). With the aim to create a system able to address Np to the CNS, we synthesized conjugates between a biodegradable copolymer, poly(D,L-lactide-co-glycolide) (PLGA), and five short peptides, by means of an amidic linkage. These peptides, that are similar to synthetic opioid peptides, were synthesized in turn by means of Fmoc solid-phase peptide synthesis. The new five modified copolymers thus obtained turned out to be valuable starting material for the preparation of Np; these were made fluorescent, in order to allow their localization after their administration, by inclusion of a fluorescent probe. The Np thus prepared were characterized (morphology, size and z-potential) and were shown to possess the peptidic moieties on their surface, as evidenced by ESCA spectroscopy. Then, their ability to cross the BBB was assessed by the in vivo Rat Brain Perfusion Technique and, in one case, by means of a systemic administration (rat femoral vein injection). Fluorescent and confocal microscopy studies showed that while PLGA Np are unable to cross the BBB, for the first time these solid Np surface-modified with peptides were shown to be able to cross the BBB. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:84 / 96
页数:13
相关论文
共 29 条
[1]   Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery [J].
Calvo, P ;
Gouritin, B ;
Chacun, H ;
Desmaële, D ;
D'Angelo, J ;
Noel, JP ;
Georgin, D ;
Fattal, E ;
Andreux, JP ;
Couvreur, P .
PHARMACEUTICAL RESEARCH, 2001, 18 (08) :1157-1166
[2]  
CASY AF, 1986, OPIOID ANALGESICS CH, P342
[3]   Biousian glycopeptides penetrate the blood-brain barrier [J].
Egleton, RD ;
Bilsky, EJ ;
Tollin, G ;
Dhanasekaran, M ;
Lowery, J ;
Alves, I ;
Davis, P ;
Porreca, F ;
Yamamura, HI ;
Yeomans, L ;
Keyari, CM ;
Polt, R .
TETRAHEDRON-ASYMMETRY, 2005, 16 (01) :65-75
[4]   Bioavailability and transport of peptides and peptide drugs into the brain [J].
Egleton, RD ;
Davis, TP .
PEPTIDES, 1997, 18 (09) :1431-1439
[5]   Improved bioavailability to the brain of glycosylated Met-enkephalin analogs [J].
Egleton, RD ;
Mitchell, SA ;
Huber, JD ;
Janders, J ;
Stropova, D ;
Polt, R ;
Yamamura, HI ;
Hruby, VJ ;
Davis, TP .
BRAIN RESEARCH, 2000, 881 (01) :37-46
[6]   Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides [J].
Elmagbari, NO ;
Egleton, RD ;
Palian, MM ;
Lowery, JJ ;
Schmid, WR ;
Davis, P ;
Navratilova, E ;
Dhanasekaran, M ;
Keyari, CM ;
Yamamura, HI ;
Porreca, F ;
Hruby, VJ ;
Polt, R ;
Bilsky, EJ .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (01) :290-297
[7]   NANOCAPSULE FORMATION BY INTERFACIAL POLYMER DEPOSITION FOLLOWING SOLVENT DISPLACEMENT [J].
FESSI, H ;
PUISIEUX, F ;
DEVISSAGUET, JP ;
AMMOURY, N ;
BENITA, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1989, 55 (01) :R1-R4
[8]   New technologies for drug delivery across the blood brain barrier [J].
Kabanov, AV ;
Batrakova, EV .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (12) :1355-1363
[9]   GLYCOSYLATED PEPTIDE-HORMONES - PHARMACOLOGICAL PROPERTIES AND CONFORMATIONAL STUDIES OF ANALOGS OF [1-DESAMINO,8-D-ARGININE] VASOPRESSIN [J].
KIHLBERG, J ;
AHMAN, J ;
WALSE, B ;
DRAKENBERG, T ;
NILSSON, A ;
SODERBERGAHLM, C ;
BENGTSSON, B ;
OLSSON, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (01) :161-169
[10]   In situ blood-brain barrier transport of nanoparticles [J].
Koziara, JM ;
Lockman, PR ;
Allen, DD ;
Mumper, RJ .
PHARMACEUTICAL RESEARCH, 2003, 20 (11) :1772-1778